IPS-Integrated Project Services’ Post

CAR-T #celltherapy is revolutionizing the treatment of #autoimmunediseases, building on its success in tackling B cell malignancies. Recent advances in CD19-based and BCMA-based #CARTtherapies show promising results for diseases such as systemic #lupus erythematosus, idiopathic inflammatory myopathy, systemic sclerosis, and #multiplesclerosis. This groundbreaking approach, which targets and depletes autoreactive B cells, aims to reset the immune system and restore normal function. While these are innovative advancements, patient selection, safety, efficacy, and ongoing medical management are critical for improving outcomes. As the field evolves, these aspects will continue to be refined to maximize the potential of CAR-T cell therapy in autoimmune diseases. Find the full article in the comments below!

Recent advancements in cancer supportive care research are unveiling exciting prospects for enhancing patient well-being during treatment. Studies highlight the therapeutic potential of high-dose oral vitamin D in managing skin toxicities linked to cancer treatment. Additionally, the benefits of incorporating yoga into care plans are being recognized for their effectiveness in reducing cancer-related fatigue and symptoms of depression. These developments hold promise for improving the quality of life for cancer patients undergoing treatment. #CancerResearch #SupportiveCare #PatientWellBeing www.alkaohri.org

My new review "A model of dysregulated crosstalk between dendritic, natural killer, and regulatory T cells in chronic obstructive pulmonary disease" is out now! Here, we highlight recent advances in Natural Killer cell, Dendritic Cell, and T-Regulatory cell biology with relevance to COPD, discuss their pairwise bidirectional interactions, and identify knowledge gaps that must be bridged to develop novel therapies. Link Below! https://lnkd.in/gxtJQudd

Labcorp Oncology’s IntelliGEN® Myeloid panel identifies somatic mutations useful in providing diagnostic, prognostic and predictive information for patients with myeloid malignancies. Learn more about IntelliGEN® Myeloid: https://lnkd.in/ezxQEhib

Discover the innovative potential of targeting lymphatic function in cardiovascular-kidney-metabolic (CKM) syndrome! The article explores how enhancing lymphatic function could revolutionize treatment by addressing multiple pathologies simultaneously. Learn more about promising therapeutic targets that might shape the future of CKM therapy. Read the full article here 🔗 https://bit.ly/3VT0LwT #CaReMeO2024 #diabetes #cardiovasculardisease #renaldisease #primarycarephysicians

#Blognews | New diagnostic technique allows detection of neurodegenerative diseases by a simple visual test based on modifications in protein surface characteristics of misfolded alpha-synuclein protein. Read our latest blog article: https://lnkd.in/dGbK4rNB Scantox Neuro GmbH is a part of the #Discovery division at Scantox Group. Follow us on 👉🏼 https://lnkd.in/dPzz2XSQ to learn more about our full #preclinical service offering. #Scantox #DrugDiscovery #preclinical

Recent Research Advances of Fabry Disease - Cerebrovascular manifestations   Dear readers, We would like to share a nice Review with you "Cerebrovascular disorders and Fabry disease d" https://lnkd.in/gpw9BSTz (click to download the PDF for free) from Dr. Ricardo Reisin, which we hope it will be helpful and useful to your research. Our journal welcomes high-quality articles, we sincerely invite you to contribute an article related to rare disease or orphan drugs to our journal. To fully support our authors to publishing high quality articles in our journal, the invited articles will undergo standard peer review process and enjoy fast publishing service.   About RDODJ: https://lnkd.in/g6_xPjbs   Rare Disease and Orphan Drugs Journal always welcome your submissions. #raredisease #Fabry #Fabry disease #Cerebrovascular #Ricardo Reisin

⚡ There is untapped power in the #Placebo effect ⚡ More than simply imagining you are feeling better, the placebo effect activates the same neural signaling pathways that occur during healing... with surprisingly beneficial results 📈 Emerging data suggest it may be possible to harness the placebo effect to improve #pain, #fatigue and other common #rheumatology symptoms. However, many questions remain. 💊 “We can improve your symptoms with pharmaceutical approaches,” Dr. Luana Colloca at the University of Maryland School of Nursing told Healio. “But we can improve those symptoms even more by engaging your mind. We need to let patients know they are empowered, that by exploring the power of their mind, they have it within themselves to take control of their disease.” Healio sat down with experts to explore the limits of the #PlaceboEffect ― it won't drive viral load to non-detectable levels or cure #cancer ― and how it can be utilized to improve #qualityoflife and relieve many of the complaints and concerns that patients report to their #rheumatologists. Join the conversation 💬 https://bit.ly/3wnOhnJ

Oculis just announced Positive Topline Results of Phase 2b RELIEF Trial with Licaminlimab/OCS-02, a game-changing approach in treating Dry Eye Disease through precision medicine. Key highlights from the trial: - Notable improvements in multiple efficacy endpoints, with more pronounced effects in the TNFR1 genetic biomarker population. - Patients with the TNFR1 biomarker demonstrated a 7-fold higher response on symptoms and 5-fold higher response on signs, showcasing the potential of personalized treatment approaches in about 20% of DED patients. With these un­prece­dent­ed results from the Relief trial we are now focused on accelerating Licaminlimab/OCS-02 development plans to address the unmet needs of individuals suffering from Dry Eye, a condition known for its lack of consistently effective and well-tolerated treatments due to population heterogeneity. #Oculis #DryEyeDisease #PrecisionMedicine #HealthcareInnovation

Thyroid eye disease (TED) is a complex autoimmune disorder where the immune system mistakenly attacks the tissues around the eyes, causing swelling, bulging, and pain.  Advances in our understanding of TED's pathogenesis have identified that inflammatory pathways are at the core of the disease, leading to research into novel therapies that offer the potential for better patient outcomes. Learn more about our lead candidate, TOUR006, and how it’s targeting underlying inflammatory pathways and being investigated as a potential new way to treat thyroid eye disease:  https://bit.ly/4eD5Ku1  #biotechnology #eyehealth #drugdevelopment